Organism: Homo sapiens
Gene: 38861_at
Selected probe(set): 206345_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38861_at (206345_s_at) across 6431 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-9.088594
Number of Samples:8 / 12

Experimental	hepatocyte (ESC)
	Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control	HepaRG
	Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

Relative Expression (log2-ratio):-8.868397
Number of Samples:9 / 12

Experimental	Hep-G2
	Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:
Control	HepaRG
	Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

Relative Expression (log2-ratio):-5.5664883
Number of Samples:4 / 5

Experimental	hepatoblastoma study 1 (mixed epithelial and mesenchymal)
	Liver tumor tissue samples from children with hepatoblastoma (mesenchymal type (MEM-HB); mixed epithelial and mesenchymal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control	normal liver tissue
	Normal liver tissue samples.

Relative Expression (log2-ratio):-5.298958
Number of Samples:3 / 12

Experimental	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG)
	HepaRG cells exposed to 7500 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Chemical was added at day 19 of cultivation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:---
Control	vehicle (DMSO) treated HepaRG cell sample
	HepaRG cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Firstly, cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Then the vehicle was added.

Relative Expression (log2-ratio):-5.162652
Number of Samples:12 / 5

Experimental	hepatoblastoma study 1 (epithelial mixed)
	Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); epithelial mixed subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control	normal liver tissue
	Normal liver tissue samples.

Relative Expression (log2-ratio):-5.113366
Number of Samples:5 / 5

Experimental	hepatoblastoma study 1 (NOS)
	Liver tumor tissue samples from children with hepatoblastoma (NOS). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control	normal liver tissue
	Normal liver tissue samples.

Relative Expression (log2-ratio):-4.8058367
Number of Samples:3 / 10

Experimental	HCC study 18 (very advanced)
	Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control	normal liver tissue
	Normal liver tissue samples obtained from the healthy livers of patients undergoing resection for hepatic hemangioma, focal nodular hyperplasia, adenoma/cystadenoma, neuroendocrine tumor, and living donor liver transplantation.

Relative Expression (log2-ratio):-4.687091
Number of Samples:3 / 17

Experimental	HCC study 18 (very advanced)
	Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control	dysplastic liver nodule study 1
	Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

Relative Expression (log2-ratio):-4.5478306
Number of Samples:7 / 5

Experimental	hepatoblastoma study 1 (embryonal)
	Liver tumor tissue samples from children with hepatoblastoma (epithelial type (E-HB); embryonal subtype). Tumors were integrase interactor 1–negative (INI1 or SMARCB1) as recommended by the International ConsensusHBClassification group.
Control	normal liver tissue
	Normal liver tissue samples.

Relative Expression (log2-ratio):-4.3371286
Number of Samples:3 / 13

Experimental	HCC study 18 (very advanced)
	Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control	hepatitis C study 10
	Cirrhotic tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Ten out of 13 samples were obtained from patients with hepatocellular carcinoma. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.